BlueCrest Capital Management Ltd Invests $1.30 Million in Alnylam Pharmaceuticals, Inc. (ALNY)

BlueCrest Capital Management Ltd bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 16,347 shares of the biopharmaceutical company’s stock, valued at approximately $1,304,000.

Several other large investors have also recently modified their holdings of the company. Gotham Asset Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $772,000. Nexthera Capital LP purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $8,375,000. Janus Henderson Group PLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $53,226,000. Farallon Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $15,952,000. Finally, PDT Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $23,537,000. Institutional investors and hedge funds own 94.25% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 124.53 on Friday. The firm has a 50 day moving average price of $99.20 and a 200-day moving average price of $76.88. The firm’s market capitalization is $11.42 billion. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $126.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same quarter in the prior year, the business posted ($1.05) EPS. Alnylam Pharmaceuticals’s revenue was up 82.9% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

ALNY has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 11th. Nomura began coverage on Alnylam Pharmaceuticals in a report on Thursday, September 14th. They issued a “reduce” rating and a $56.00 price target for the company. ValuEngine upgraded Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Instinet began coverage on Alnylam Pharmaceuticals in a report on Friday, September 15th. They issued a “reduce” rating and a $56.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $100.80.

ILLEGAL ACTIVITY NOTICE: “BlueCrest Capital Management Ltd Invests $1.30 Million in Alnylam Pharmaceuticals, Inc. (ALNY)” was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/10/13/bluecrest-capital-management-ltd-invests-1-30-million-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply